USING QVAR®

Help Your Patients Control Asthma Symptoms

QVAR® is a long-term control medication for asthma.1 QVAR® provides good lung deposition, even among adults with poor inhaler technique.2 QVAR® doesn't need shaking and can be used with or without a spacer,1 making it a good choice for a wide range of patients, including children as young as 5 years old.1

Patients Can Use QVAR® With or Without Spacers

QVAR® can be used with or without a spacer.1 Potential benefits of using QVAR® without a spacer include:

  • Eliminating the cost of a spacer
  • No need to train patients on spacer use and cleaning
  • 54% lung deposition without a spacer in children 11-14 years of age.3

Consider QVAR® for patients who are transitioning from a nebulizer.

Learn More About QVAR®

Read on for important information about QVAR® dosing in adults and children, helping patients maintain adherence, and initiating asthma control therapy with QVAR® for patients with mild to moderate persistent asthma.

QVAR® (beclomethasone dipropionate HFA) Inhalation Aerosol is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age or older. QVAR® is also indicated for asthma patients who require systemic corticosteroid administration, where adding QVAR® may reduce or eliminate the need for systemic corticosteroids.

Important Safety Information

  • QVAR® is not a bronchodilator and is not indicated for relief of acute bronchospasm
  • Common side effects associated with the use of QVAR® and placebo in clinical trials include, but are not limited to, headache (12% and 9%, respectively) and pharyngitis (8% and 4%, respectively)
CAUTION: Adrenal insufficiency may occur when transferring patients from systemic steroids (see WARNINGS, Prescribing Information).
  • A reduction in growth velocity in growing children and teenagers may occur as a result of inadequate control of chronic diseases such as asthma or from use of corticosteroids for treatment

References

  1. QVAR® (beclomethasone dipropionate HFA) Prescribing Information. Teva Respiratory, LLC; 2010.
  2. Leach C. Effect of formulation parameters on hydrofluoroalkane-beclomethasone dipropionate drug deposition in humans. J Allergy Clin Immunol.1999;104(6):S250-S252.
  3. Devadason SG, Huang T, Walker S, Troedson R, Le Souef PN. Distribution of technetium-99m-labelled QVAR® delivered using an Autohaler™ device in children. Eur Respir J. 2003;21(6):1007-1011.
111765